Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Merck Singulair Formulary Status Stable; Restricted Use In Subset Of Plans

  • News

Executive Summary

Merck's Singulair allergic rhinitis indication is gaining formulary status in the majority of managed care accounts despite the availability of OTC Claritin, the company told investors April 21

You may also be interested in...



Schering Global Pharma President Cox To Tackle Flagging Allergy Sales

The first priority for Schering-Plough's new Global Pharmaceutical President Carrie Cox will be implementing marketing changes for the company's allergy franchise

Schering Global Pharma President Cox To Tackle Flagging Allergy Sales

The first priority for Schering-Plough's new Global Pharmaceutical President Carrie Cox will be implementing marketing changes for the company's allergy franchise

Mass. Medicaid Leukotriene Blocker Limitation Seeks To Curb Allergy Use

Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By